# SELTA SQUARE

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/selta-square

- Industry: Pharmaceuticals
- Headquarters: Seoul, South Korea
- Website: www.seltaglobal.com/
- Total disclosed funding: $6.4M
- Latest round: Series A (Jan 27, 2025)
- Investors on record: 5

## About

Founded in 2021, and based in Seoul, South Korea, SELTA SQUARE operates as a pharmacovigilance company that uses AI-based technologies to provide drugs efficiency monitoring services. Through its platform users can get information of the efficiency of new pharmaceutical products. In May 2023, SELTA SQUARE raised seed funding from new investor Korea Tech Incubator for Startup, being selected for Accelerator Investment-Driven Tech Incubator Program. Financial terms of the deal were not disclosed. As of 2023, the company is led by its CEO Minkyung Shin.

## Funding rounds

- Series A, Jan 27, 2025, $6.4M — KB Investment, Korea Investment Partners, Yuanta Investment, SJ Investment Partners, Genaxis
- Seed, Dec 19, 2022 — Genaxis

## Investors

- Genaxis (https://capitalatlas.ai/funds/genaxis) — Seed, Series A
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series A
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A
- Yuanta Investment (https://capitalatlas.ai/funds/yuanta-investment) — Series A
- SJ Investment Partners (https://capitalatlas.ai/funds/sj-investment-partners) — Series A